Samuel Moed - 01 Jan 2023 Form 3 Insider Report for BiondVax Pharmaceuticals Ltd. (BVXV)

Role
Director
Signature
/s/ Samuel Moed
Issuer symbol
BVXV
Transactions as of
01 Jan 2023
Transactions value $
$0
Form type
3
Filing time
05 Jan 2023, 11:48:20 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BVXV Stock Options (right to buy) 01 Jan 2023 Ordinary Shares 720,000 $0.182 Direct F1, F2
holding BVXV Stock Options (right to buy) 01 Jan 2023 Ordinary Shares 3,280,000 $0.174 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options were granted on March 24, 2020 and are fully vested.
F2 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents four hundred Ordinary Shares.
F3 Stock options were granted on September 2, 2020 and vest on a quarterly basis for a period of three years.